Completion dissection or observation for sentinel-node metastasis in melanoma

New England Journal of Medicine

Volumn 376, Issue 23, 2017, Pages 2211-2222

  Faries, B ^a   Thompson, J F ^b   Cochran, A J ^b   Andtbacka, R H ^g   Mozzillo, N ^a   Zager, J S ^l   Jahkola, T ^m   Bowles, T L ^h   Testori, A ^j   Beitsch, P D ⁿ   Hoekstra, H J ^o   Moncrieff, M ^q   Ingvar, C ^s   Wouters, M W J M ^p   Sabel, M S ^t   Levine, E A ^u   Agnese, D ^v   Henderson, M ^d   Dummer, R ^w   Rossi, C R ^k   Neves, R I ^y   Trocha, S D ^ag   Wright, F ^ae   Byrd, D R ^af   Matter, M ^x   Hsueh, E ^ae   MacKenzie Ross, A ^r   Johnson, D B ^aj   Terheyden, P ^ai   Berger, A C ^z   Huston, T L ^ad   Wayne, J D ^ah   Smithers, B M ^e   Neuman, H B ^aa   Schneebaum, S ^ac   Gershenwald, J E ^ak   Ariyan, C E ^al   Desai, D C ^ab   Jacobs, L ^am   McMasters, K M ^an   Gesierich, A ^ao   Hersey, P ^aq   Bines, S D ^ap   Kane, J M ^ar   Barth, R J ^av   McKinnon, G ^at   Farma, J M ^au   Schultz, E ^aw   Vidal Sicart, S ^as   Hoefer, R A ^av   Lewis, J M ^ax   Scheri, R ^f   Kelley, M C ⁱ   Nieweg, O E ^c   Noyes, R D ^g   Hoon, D S B ^a   Wang, H J ^b   Elashoff, D A ^b   Elashoff, R M ^b   more..

^a JOHN WAYNE CANCER INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF SYDNEY   (Australia)

^d PETER MACCALLUM CANCER CENTRE   (Australia)

^e PRINCESS ALEXANDRA HOSPITAL   (Australia)

^f Newcastle Melanoma Unit   (Australia)

^g UNIVERSITY OF UTAH   (United States)

^h INTERMOUNTAIN MEDICAL CENTER   (United States)

ⁱ NATIONAL CANCER INSTITUTE   (Italy)

^j EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^k UNIVERSITY OF PADOVA   (Italy)

^l H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^m HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

ⁿ Dallas Surgical Group   (United States)

^o UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^p NETHERLANDS CANCER INSTITUTE   (Netherlands)

^q NORFOLK AND NORWICH UNIVERSITY HOSPITAL   (United Kingdom)

^r GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^s LUND UNIVERSITY HOSPITAL   (Sweden)

^t UNIVERSITY OF MICHIGAN   (United States)

^u WAKE FOREST UNIVERSITY   (United States)

^v OHIO STATE UNIVERSITY   (United States)

^w UNIVERSITY OF ZURICH   (Switzerland)

^x LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^y PENN STATE CANCER INSTITUTE   (United States)

^z THOMAS JEFFERSON UNIVERSITY   (United States)

^aa FOX CHASE CANCER CENTER   (United States)

^ab ST LUKE S UNIVERSITY HEALTH NETWORK   (United States)

^ac GREENVILLE HOSPITAL SYSTEM   (United States)

^ad Canada   (Canada)

^ae TOM BAKER CANCER CENTRE   (Canada)

^af UNIVERSITY OF WASHINGTON   (United States)

^ag SAINT LOUIS UNIVERSITY   (United States)

^ah VANDERBILT UNIVERSITY   (United States)

^ai UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^aj UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^ak City Hospital of Nörnberg   (Germany)

^al STONY BROOK UNIVERSITY   (United States)

^am MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^an ROSWELL PARK CANCER INSTITUTE   (United States)

^ao NORTHWESTERN UNIVERSITY   (United States)

^ap RUSH UNIVERSITY MEDICAL CENTER   (United States)

^aq UNIVERSITY OF WISCONSIN MADISON   (United States)

^ar TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^as Dermatology Service   (United States)

^at JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^au UNIVERSITY OF LOUISVILLE   (United States)

^av DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^aw HOSPITAL CLÍNIC   (Spain)

^ax Sentara Careplex Hospital   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CANCER CONTROL; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SPECIFIC SURVIVAL; CLINICAL OBSERVATION; CONTROLLED STUDY; DISEASE FREE SURVIVAL; ECHOGRAPHY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LYMPH NODE DISSECTION; LYMPHEDEMA; MAJOR CLINICAL STUDY; MALE; MELANOMA; MOLECULAR DIAGNOSIS; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SENTINEL LYMPH NODE METASTASIS; SURVIVAL RATE; ADVERSE EFFECTS; CANCER STAGING; CLINICAL TRIAL; COMPARATIVE STUDY; DIAGNOSTIC IMAGING; INTENTION TO TREAT ANALYSIS; LYMPH NODE; LYMPHATIC METASTASIS; MIDDLE AGED; MORTALITY; PATHOLOGY; PHASE 3 CLINICAL TRIAL; POSTOPERATIVE COMPLICATION; PROCEDURES; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; SECONDARY; SENTINEL LYMPH NODE; SENTINEL LYMPH NODE BIOPSY; SURVIVAL ANALYSIS; WATCHFUL WAITING; YOUNG ADULT;

ADULT; AGED; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INTENTION TO TREAT ANALYSIS; LYMPH NODE EXCISION; LYMPH NODES; LYMPHATIC METASTASIS; LYMPHEDEMA; MALE; MELANOMA; MIDDLE AGED; NEOPLASM STAGING; POSTOPERATIVE COMPLICATIONS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; SENTINEL LYMPH NODE; SENTINEL LYMPH NODE BIOPSY; SURVIVAL ANALYSIS; ULTRASONOGRAPHY; WATCHFUL WAITING; YOUNG ADULT;

EID: 85020241826     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1613210     Document Type: Article

References (21)

1. Morton DL, Cochran AJ, Thompson JF, et al. Sentinel node biopsy for earlystage melanoma: Accuracy and morbidity in MSLT-I, an international multicenter trial. Ann Surg 2005; 242: 302-11.
2. Morton DL, Thompson JF, Cochran AJ, et al. Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med 2006; 355: 1307-17.
3. Morton DL, Thompson JF, Cochran AJ, et al. Final trial report of sentinel-node biopsy versus nodal observation in melanoma. N Engl J Med 2014; 370: 599-609.
4. Wong SL, Balch CM, Hurley P, et al. Sentinel lymph node biopsy for melanoma: American Society of Clinical Oncology and Society of Surgical Oncology joint clinical practice guideline. J Clin Oncol 2012; 30: 2912-8.
5. Australian Cancer Network Melanoma Guidelines Revision Working Party. Clinical practice guidelines for the management of melanoma in Australia and New Zealand. Wellington, New Zealand: Cancer Council Australia/Australian Cancer Network, October 2008.
6. Garbe C, Peris K, Hauschild A, et al. Diagnosis and treatment of melanoma: European consensus-based interdisciplinary guideline-update 2012. Eur J Cancer 2012; 48: 2375-90.
7. Coit DG, Thompson JA, Algazi A, et al. NCCN guidelines insights: melanoma, version 3.2016. J Natl Compr Canc Netw 2016; 14: 945-58.
8. Faries MB, Thompson JF, Cochran A, et al. The impact on morbidity and length of stay of early versus delayed complete lymphadenectomy in melanoma: results of the Multicenter Selective Lymphadenectomy Trial (I). Ann Surg Oncol 2010; 17: 3324-9.
9. Lee DY, Lau BJ, Huynh KT, et al. Impact of completion lymph node dissection on patients with positive sentinel lymph node biopsy in melanoma. J Am Coll Surg 2016; 223: 9-18.
10. Bamboat ZM, Konstantinidis IT, Kuk D, Ariyan CE, Brady MS, Coit DG. Observation after a positive sentinel lymph node biopsy in patients with melanoma. Ann Surg Oncol 2014; 21: 3117-23.
11. Wong SL, Morton DL, Thompson JF, et al. Melanoma patients with positive sentinel nodes who did not undergo completion lymphadenectomy: A multi-institutional study. Ann Surg Oncol 2006; 13: 809-16.
12. Leiter U, Stadler R, Mauch C, et al. Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): A multicentre, randomised, phase 3 trial. Lancet Oncol 2016; 17: 757-67.
13. Reintgen M, Murray L, Akman K, et al. Evidence for a better nodal staging system for melanoma: The clinical relevance of metastatic disease confined to the sentinel lymph nodes. Ann Surg Oncol 2013; 20: 668-74.
14. Leung AM, Morton DL, Ozao-Choy J, et al. Staging of regional lymph nodes in melanoma: A case for including nonsentinel lymph node positivity in the American Joint Committee on Cancer staging system. JAMA Surg 2013; 148: 879-84.
15. Takeuchi H, Morton DL, Kuo C, et al. Prognostic significance of molecular upstaging of paraffin-embedded sentinel lymph nodes in melanoma patients. J Clin Oncol 2004; 22: 2671-80.
16. Snow HM. Melanotic cancerous disease. Lancet 1892; 140: 869-922.
17. McMasters KM, Egger ME, Edwards MJ, et al. Final results of the Sunbelt Melanoma Trial: A multi-institutional prospective randomized phase III study evaluating the role of adjuvant high-dose interferon alfa-2b and completion lymph node dissection for patients staged by sentinel lymph node biopsy. J Clin Oncol 2016; 34: 1079-86.
18. Cochran AJ, Wen DR, Huang RR, Wang HJ, Elashoff R, Morton DL. Prediction of metastatic melanoma in nonsentinel nodes and clinical outcome based on the primary melanoma and the sentinel node. Mod Pathol 2004; 17: 747-55.
19. Starz H, Welzel J, Bertsch HP, Kretschmer L. Tumor penetrative depth considers both the size of sentinel lymph node metastases and their location in relation to the nodal capsule. J Clin Oncol 2011; 29: 4843-4.
20. Chakera AH, Hesse B, Burak Z, et al. EANM-EORTC general recommendations for sentinel node diagnostics in melanoma. Eur J Nucl Med Mol Imaging 2009; 36: 1713-42.
21. Altstein LL, Li G, Elashoff RM. A method to estimate treatment efficacy among latent subgroups of a randomized clinical trial. Stat Med 2011; 30: 709-17.